Aptuit LLC Names Dinkelacker and Duffield to Executive Leadership Team

Aptuit LLC Names Dinkelacker and Duffield to Executive Leadership Team

4/10/2013 3:18:46 PM

Greenwich, CT, April 10, 2013 – Aptuit LLC announces the appointment of two new members to its Executive Leadership team. Kurt Dinkelacker has been named Executive Vice President and Chief Financial Officer and Kevin Duffield has been promoted to Vice President, Sales and Business Development.
As Executive Vice President and Chief Financial Officer, Mr. Dinkelacker is reporting directly to Stuart Needleman, Aptuit's President and COO. Mr. Dinkelacker brings substantial experience in managing global financial operations in growth-focused corporations. Previously, he was an Executive Vice President and CFO at Retrievex, also a Welsh, Carson, Anderson & Stowe portfolio company. Before that, he held leadership positions at Financing Alternatives, TeleSpectrum Worldwide and IKON Office Solutions. A graduate of Drexel University where he earned a BA in Accounting and an MBA in its Executive graduate program, Mr. Dinkelacker is the recipient of the University's 1998 Alumni Award.

Kevin Duffield takes on new responsibilities as Aptuit's Vice President, Sales and Business Development. He will be handling global sales and marketing, also reporting directly to Stuart Needleman. While the coordinated sales effort continues to be focused at the site function level, under Kevin's leadership, all sales efforts will be leveraged. Under his supervision, cross selling initiatives and new opportunities from Aptuit's vast range of capabilities and disciplines are anticipated. Kevin has more than 25 years experience in pharmaceutical contract manufacturing services. He has held several leadership positions in sales, business development, and operations of cGMP development and manufacturing facilities. Before he joined Aptuit, Kevin gained diverse experience while he was employed at Eastman Fine Chemicals, ChiRex and NovaSep. Kevin holds a Bachelor's Degree in Chemistry from Illinois State University.

In discussing these new appointments, Mr. Needleman said, "We congratulate these professionals and look forward to their contributions to our Executive Leadership team. We've put a great deal of effort in finding the people who represent our 'uncommon expertise' across a range of disciplines. These two proven pros are valuable additions to our team, ready to implement a strategy that will help steer Aptuit to its position as a market-leading provider of early to mid-phase integrated drug discovery and development."

For more information or to arrange an interview, please contact Maria Garvey at Delfino Marketing either by phone at 914-747-1400 or by email: [email protected]

Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Sterile Fill Finish & Formulation Development, Oral Dosage Form Development & Manufacture, Clinical Sciences, Consulting and Aptuit INDiGOÒ (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.

For more information about Aptuit, visit www.aptuit.com

Suggested Articles

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Novartis is picking up Vedere Bio and its preclinical gene therapies for $150 million upfront, with the promise of another $130 million.

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.